Literature DB >> 23729499

Regulatory T cell epitopes (Tregitopes) in IgG induce tolerance in vivo and lack immunogenicity per se.

Yan Su1, Robert Rossi, Anne S De Groot, David W Scott.   

Abstract

Tregitopes are a set of epitopes, derived from IgG, that bind to MHCII, activate nTregs, and promote tolerance. We have now confirmed that coadministration of Tregitopes with a range of proteins (autoantigens and nominal antigens, such as OVA) in vitro and in vivo leads to suppression of T cell and antibody responses to the test antigens. In this study, we demonstrate that Tregitopes are not immunogenic in vivo even when emulsified with strong adjuvants, such as IFA or CFA. Moreover, in vivo administration of Tregitopes with IFA or CFA does not induce Th1 or Th2 cytokine expression under restimulation conditions in vitro. We investigated tolerance induction by codelivering Tregitopes with OVA using B cells. When B cells were pulsed with OVA plus Tregitopes and transferred into naïve mice, we found that cellular and humoral immune responses to the OVA were suppressed. As a result of their ability to induce Tregs and the absence of immunogenicity in the context of strong adjuvants, Tregitopes might be considered a novel immunomodulatory approach for the suppression of immune responses to protein therapeutics (such as FVIII and mAb), as well as for treatment of autoimmune diseases.

Entities:  

Keywords:  IVIg; Treg; immunomodulation

Mesh:

Substances:

Year:  2013        PMID: 23729499      PMCID: PMC3714563          DOI: 10.1189/jlb.0912441

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  37 in total

Review 1.  Monoclonal antibody and intravenous immunoglobulin therapy for rheumatic diseases: rationale and mechanisms of action.

Authors:  Jagadeesh Bayry; Sébastien Lacroix-Desmazes; Michel D Kazatchkine; Srini V Kaveri
Journal:  Nat Clin Pract Rheumatol       Date:  2007-05

Review 2.  Can we prevent immunogenicity of human protein drugs?

Authors:  D W Scott; A S De Groot
Journal:  Ann Rheum Dis       Date:  2010-01       Impact factor: 19.103

3.  B-cell delivered gene therapy for tolerance induction: role of autoantigen-specific B cells.

Authors:  Ai-Hong Zhang; Xin Li; Olusegun O Onabajo; Yan Su; Jonathan Skupsky; James W Thomas; David W Scott
Journal:  J Autoimmun       Date:  2010-07-01       Impact factor: 7.094

4.  B-cell based gene therapy for autoimmune diseases.

Authors:  David W Scott; Ai-Hong Zhang; Yan Su
Journal:  Infect Disord Drug Targets       Date:  2012-06

5.  Tolerance induction via a B-cell delivered gene therapy-based protocol: optimization and role of the Ig scaffold.

Authors:  Tie Chi Lei; Yan Su; David W Scott
Journal:  Cell Immunol       Date:  2005-08-10       Impact factor: 4.868

Review 6.  Pathophysiology of inhibitors to factor VIII in patients with haemophilia A.

Authors:  S Lacroix-Desmazes; N Misra; J Bayry; C Artaud; B Drayton; S V Kaveri; M D Kazatchkine
Journal:  Haemophilia       Date:  2002-05       Impact factor: 4.287

7.  Gene transfer of Ig-fusion proteins into B cells prevents and treats autoimmune diseases.

Authors:  Marco E F Melo; Jiahua Qian; Moustapha El-Amine; Rajeev K Agarwal; Nadejda Soukhareva; Yubin Kang; David W Scott
Journal:  J Immunol       Date:  2002-05-01       Impact factor: 5.422

8.  B cells induce tolerance by presenting endogenous peptide-IgG on MHC class II molecules via an IFN-gamma-inducible lysosomal thiol reductase-dependent pathway.

Authors:  Yan Su; Gregory Carey; Maja Maric; David W Scott
Journal:  J Immunol       Date:  2008-07-15       Impact factor: 5.422

Review 9.  Tregitope update: mechanism of action parallels IVIg.

Authors:  Leslie P Cousens; Ryan Tassone; Bruce D Mazer; Vasanthi Ramachandiran; David W Scott; Anne S De Groot
Journal:  Autoimmun Rev       Date:  2012-08-28       Impact factor: 9.754

10.  Teaching tolerance: New approaches to enzyme replacement therapy for Pompe disease.

Authors:  Leslie P Cousens; Federico Mingozzi; Sander van der Marel; Yan Su; Richard Garman; Valerie Ferreira; William Martin; David W Scott; Anne S De Groot
Journal:  Hum Vaccin Immunother       Date:  2012-10-01       Impact factor: 3.452

View more
  10 in total

1.  Preclinical development of HIvax: Human survivin highly immunogenic vaccines.

Authors:  Peter R Hoffmann; Maddalena Panigada; Elisa Soprana; Frances Terry; Ivo Sah Bandar; Andrea Napolitano; Aaron H Rose; Fukun W Hoffmann; Lishomwa C Ndhlovu; Mahdi Belcaid; Lenny Moise; Anne S De Groot; Michele Carbone; Giovanni Gaudino; Takashi Matsui; Antonio Siccardi; Pietro Bertino
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 2.  Inhibitors - cellular aspects and novel approaches for tolerance.

Authors:  D W Scott
Journal:  Haemophilia       Date:  2014-05       Impact factor: 4.287

3.  Intravenous immunoglobulin suppresses the polarization of both classically and alternatively activated macrophages.

Authors:  Chaitrali Saha; Prathap Kothapalli; Veerupaxagouda Patil; Gundallahalli Bayyappa ManjunathaReddy; Srini V Kaveri; Jagadeesh Bayry
Journal:  Hum Vaccin Immunother       Date:  2019-05-07       Impact factor: 3.452

Review 4.  Tolerogenic properties of the Fc portion of IgG and its relevance to the treatment and management of hemophilia

Authors:  Richard S Blumberg; David Lillicrap
Journal:  Blood       Date:  2018-03-27       Impact factor: 22.113

Review 5.  Tregitope peptides: the active pharmaceutical ingredient of IVIG?

Authors:  Anne S De Groot; Leslie Cousens; Federico Mingozzi; William Martin
Journal:  Clin Dev Immunol       Date:  2013-12-25

6.  Development of Gene Transfer for Induction of Antigen-specific Tolerance.

Authors:  Brandon K Sack; Roland W Herzog; Cox Terhorst; David M Markusic
Journal:  Mol Ther Methods Clin Dev       Date:  2014-04-30       Impact factor: 6.698

Review 7.  Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics.

Authors:  Jasmine Davda; Paul Declerck; Siwen Hu-Lieskovan; Timothy P Hickling; Ira A Jacobs; Jeffrey Chou; Shahram Salek-Ardakani; Eugenia Kraynov
Journal:  J Immunother Cancer       Date:  2019-04-15       Impact factor: 13.751

Review 8.  Immunomodulation in Primary Immune Thrombocytopenia: A Possible Role of the Fc Fragment of Romiplostim?

Authors:  Alexandra Schifferli; Falk Nimmerjahn; Thomas Kühne
Journal:  Front Immunol       Date:  2019-06-04       Impact factor: 7.561

9.  Therapeutic administration of Tregitope-Human Albumin Fusion with Insulin Peptides to promote Antigen-Specific Adaptive Tolerance Induction.

Authors:  Anne S De Groot; Gail Skowron; James Robert White; Christine Boyle; Guilhem Richard; David Serreze; William D Martin
Journal:  Sci Rep       Date:  2019-11-06       Impact factor: 4.379

Review 10.  Beyond humanization and de-immunization: tolerization as a method for reducing the immunogenicity of biologics.

Authors:  Anne S De Groot; Frances Terry; Leslie Cousens; William Martin
Journal:  Expert Rev Clin Pharmacol       Date:  2013-11       Impact factor: 5.045

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.